BR112016020053A2 - métodos de previsão da reação de pacientes que sofrem de distúrbio inflamatório, de previsão da capacidade de reação de pacientes, de identificação de pacientes que sofrem de distúrbio inflamatório e de seu tratamento, usos de kit e kits - Google Patents

métodos de previsão da reação de pacientes que sofrem de distúrbio inflamatório, de previsão da capacidade de reação de pacientes, de identificação de pacientes que sofrem de distúrbio inflamatório e de seu tratamento, usos de kit e kits

Info

Publication number
BR112016020053A2
BR112016020053A2 BR112016020053-5A BR112016020053A BR112016020053A2 BR 112016020053 A2 BR112016020053 A2 BR 112016020053A2 BR 112016020053 A BR112016020053 A BR 112016020053A BR 112016020053 A2 BR112016020053 A2 BR 112016020053A2
Authority
BR
Brazil
Prior art keywords
kits
predicting
inflammatory disorder
methods
patients suffering
Prior art date
Application number
BR112016020053-5A
Other languages
English (en)
Portuguese (pt)
Inventor
A. HACKNEY Jason
Keir Mary
Wei Tew Gaik
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of BR112016020053A2 publication Critical patent/BR112016020053A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112016020053-5A 2014-03-27 2015-03-26 métodos de previsão da reação de pacientes que sofrem de distúrbio inflamatório, de previsão da capacidade de reação de pacientes, de identificação de pacientes que sofrem de distúrbio inflamatório e de seu tratamento, usos de kit e kits BR112016020053A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461971379P 2014-03-27 2014-03-27
US61/971,379 2014-03-27
PCT/US2015/022762 WO2015148809A1 (en) 2014-03-27 2015-03-26 Methods for diagnosing and treating inflammatory bowel disease

Publications (1)

Publication Number Publication Date
BR112016020053A2 true BR112016020053A2 (pt) 2018-02-20

Family

ID=54196399

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016020053-5A BR112016020053A2 (pt) 2014-03-27 2015-03-26 métodos de previsão da reação de pacientes que sofrem de distúrbio inflamatório, de previsão da capacidade de reação de pacientes, de identificação de pacientes que sofrem de distúrbio inflamatório e de seu tratamento, usos de kit e kits

Country Status (15)

Country Link
US (4) US10273542B2 (https=)
EP (1) EP3122377A4 (https=)
JP (3) JP7054990B2 (https=)
KR (2) KR20220065091A (https=)
CN (2) CN113604543A (https=)
AR (1) AR099856A1 (https=)
AU (3) AU2015235986B2 (https=)
BR (1) BR112016020053A2 (https=)
CA (1) CA2939246A1 (https=)
IL (2) IL247266B (https=)
MA (1) MA39804A (https=)
MX (2) MX2016012282A (https=)
RU (1) RU2016136716A (https=)
SG (1) SG11201607938UA (https=)
WO (1) WO2015148809A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2279004T3 (en) * 2008-05-16 2015-02-02 Hoffmann La Roche USE OF biomarkers for assessment of treatment of gastrointestinal inflammatory disorders WITH beta7 integrin antagonists
KR20220065091A (ko) 2014-03-27 2022-05-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
KR20170120601A (ko) * 2015-02-26 2017-10-31 제넨테크, 인크. 인테그린 베타7 길항제 및 크론병을 치료하는 방법
GB201611738D0 (en) * 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease
CN107083423B (zh) * 2017-03-27 2022-01-28 北京极客基因科技有限公司 一种药物靶点预测和药物全方面评价方法
JP7365358B2 (ja) 2018-04-12 2023-10-19 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリンα４β７のアンタゴニスト
WO2020104705A2 (en) * 2018-11-23 2020-05-28 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease
CA3128973A1 (en) 2019-03-04 2020-09-10 Bhaskar Bhattacharyya Data compression and communication using machine learning
JP2022533956A (ja) 2019-05-14 2022-07-27 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａ患者を選択する方法、システム、およびデバイス
GB2603294A (en) 2019-06-27 2022-08-03 Scipher Medicine Corp Developing classifiers for stratifying patients
WO2021076890A1 (en) 2019-10-16 2021-04-22 Morphic Therapeutic, Inc. INHIBITING HUMAN INTEGRIN α4β7
US12394524B2 (en) * 2020-07-22 2025-08-19 Iterative Scopes, Inc. Systems and methods for analysis of medical images for scoring of inflammatory bowel disease
MX2023001157A (es) 2020-07-31 2023-02-22 Genentech Inc Formulaciones de anticuerpo anti-integrina beta7 y dispositivos.
IL300978A (en) * 2020-09-01 2023-04-01 Scipher Medicine Corp Methods and systems for predicting response to anti-TNF treatments
CN118139896A (zh) * 2021-10-15 2024-06-04 南通壹宸生物医药科技有限公司 一种双特异性结合分子
CN114085908B (zh) * 2021-10-30 2023-08-08 中国人民解放军陆军军医大学第一附属医院 用于评估胶质母细胞瘤治疗效果的基因靶点组合及其应用
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4256833A (en) 1979-01-08 1981-03-17 Majid Ali Enzyme immunoassay for allergic disorders
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
FI891226A7 (fi) 1988-04-28 1989-10-29 The Board Of Trustees Of The Leland Anti-T-solun reseptorideterminantit autoimmuunisairauden hoitoon
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
EP0463101B2 (en) 1989-03-21 2003-03-19 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
ATE161850T1 (de) 1989-07-19 1998-01-15 Connetics Corp T-zell-rezeptor-peptide als heilmittel für autoimmune und bösartige krankheiten
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
AU2582897A (en) 1996-03-15 1997-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
AU5914201A (en) 2000-04-25 2001-11-07 Idec Pharma Corp Intrathecal administration of rituximab for treatment of central nervous system lymphomas
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1667669A2 (en) * 2003-05-30 2006-06-14 Molecular Staging, Inc. Inflammatory bowel diseases
US20110152115A1 (en) * 2003-09-03 2011-06-23 The United States of America, as represented by the Secretary, Department of Health and Methods for identifying, diagnosing, and predicting survival of lymphomas
RS52213B (sr) 2004-09-03 2012-10-31 Genentech, Inc. Humanizovani anti-beta7 antagonisti i njihove primene
US8030003B2 (en) * 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
JP2009519017A (ja) * 2005-12-07 2009-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性疾患の治療及び診断
CN101490085A (zh) * 2006-06-12 2009-07-22 特鲁比昂药品公司 具有效应功能的单链多价结合蛋白
US20080293582A1 (en) * 2006-08-30 2008-11-27 Xilin Li Markers and Methods for Assessing and Treating Ulcerative Colitis and Related Disorders Using a 43 Gene Panel
US20080247955A1 (en) * 2007-01-16 2008-10-09 Jun Kuai Inflammation treatment, detection and monitoring via TREM-1
JP5337055B2 (ja) * 2007-02-28 2013-11-06 メルク・シャープ・アンド・ドーム・コーポレーション 免疫性障害の処置のための組合せ治療
TW200848431A (en) * 2007-06-12 2008-12-16 Trubion Pharmaceuticals Inc Single-chain multivalent binding proteins with effector function
MX2010005080A (es) * 2007-11-07 2010-07-28 Genentech Inc Metodos y composiciones para determinar la sensibilidad de linfoma de celula b al tratamiento con anticuerpos anti-cd40.
SI2257643T1 (sl) * 2008-02-19 2018-12-31 The Children's Hospital Of Philadelphia Identifikacija predelov vnetne črevesne bolezni z začetkom v otroštvu in metode za njeno uporabo za diagnozo in zdravljenje te bolezni
US20110117111A1 (en) * 2008-03-26 2011-05-19 Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
DK2279004T3 (en) * 2008-05-16 2015-02-02 Hoffmann La Roche USE OF biomarkers for assessment of treatment of gastrointestinal inflammatory disorders WITH beta7 integrin antagonists
WO2010042903A1 (en) * 2008-10-09 2010-04-15 Alfagene Bioscience, Inc Use and identification of biomarkers for gastrointestinal diseases
US20110212104A1 (en) * 2008-11-03 2011-09-01 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
CA2758531C (en) * 2009-04-14 2018-11-13 Derren Barken Inflammatory bowel disease prognostics
CN102639710A (zh) * 2009-07-20 2012-08-15 基因泰克公司 克罗恩病的基因表达标记
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
US8766034B2 (en) * 2010-09-22 2014-07-01 Cedars-Sinai Medical Center TL1A model of inflammation fibrosis and autoimmunity
WO2012101183A2 (en) * 2011-01-25 2012-08-02 Tc Land Expression Genes and genes combinations based on gene mknk1 predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (cytd) or anti-inflammatory biological drugs
EP3412309A1 (en) * 2011-03-31 2018-12-12 F. Hoffmann-La Roche AG Methods of administering beta7 integrin antagonists
US20130040835A1 (en) * 2011-05-05 2013-02-14 Exagen Diagnostics, Inc Genes predictive of anti-TNF response in inflammatory diseases
CN102876793B (zh) * 2012-09-29 2014-03-12 山东省皮肤病性病防治研究所 单核苷酸多态性rs2058660在检测麻风病易感基因中的应用
CN102876794B (zh) * 2012-09-29 2014-07-02 山东省皮肤病性病防治研究所 单核苷酸多态性rs6871626在检测麻风病易感基因中的应用
EP2903691B1 (en) 2012-10-05 2019-05-22 F.Hoffmann-La Roche Ag Methods for diagnosing and treating inflammatory bowel disease
KR102175688B1 (ko) 2013-03-27 2020-11-06 제넨테크, 인크. 베타7 인테그린 길항제를 사용하는 위장 염증성 장애의 치료를 평가하기 위한 바이오마커의 사용
KR20220065091A (ko) * 2014-03-27 2022-05-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법

Also Published As

Publication number Publication date
CN113604543A (zh) 2021-11-05
US20200325538A1 (en) 2020-10-15
MX2022010809A (es) 2022-09-27
JP2017511131A (ja) 2017-04-20
AU2015235986A1 (en) 2016-08-25
JP7054990B2 (ja) 2022-04-15
AU2021200518B2 (en) 2021-03-04
IL247266B (en) 2020-08-31
EP3122377A1 (en) 2017-02-01
US20220186314A1 (en) 2022-06-16
MX2016012282A (es) 2017-01-06
US20190256913A1 (en) 2019-08-22
SG11201607938UA (en) 2016-10-28
AU2015235986B2 (en) 2020-12-03
JP2022043033A (ja) 2022-03-15
AU2021200518A1 (en) 2021-02-25
AU2021203296A1 (en) 2021-06-17
CA2939246A1 (en) 2015-10-01
KR20160130780A (ko) 2016-11-14
AR099856A1 (es) 2016-08-24
CN106102767B (zh) 2021-08-10
RU2016136716A (ru) 2018-04-28
IL247266A0 (en) 2016-09-29
US10669587B2 (en) 2020-06-02
KR20220065091A (ko) 2022-05-19
EP3122377A4 (en) 2018-03-14
IL276516A (en) 2020-09-30
US20170233809A1 (en) 2017-08-17
US11261493B2 (en) 2022-03-01
MA39804A (fr) 2017-02-01
US10273542B2 (en) 2019-04-30
CN106102767A (zh) 2016-11-09
JP2020062013A (ja) 2020-04-23
KR102397324B1 (ko) 2022-05-13
WO2015148809A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
BR112016020053A2 (pt) métodos de previsão da reação de pacientes que sofrem de distúrbio inflamatório, de previsão da capacidade de reação de pacientes, de identificação de pacientes que sofrem de distúrbio inflamatório e de seu tratamento, usos de kit e kits
SG10201901076WA (en) Methods of treating alzheimer's disease
MX372664B (es) Un antagonista de integrina beta7 para usarse en diagnosticar y tratar la enfermedad inflamatoria intestinal.
CL2016000883A1 (es) Compuestos macrocíclicos, inhibidores de antígeno prostático específico de membrana (psma); composición farmacéutica; complejo de metal; y su uso para preparar compuestos radiomarcados útiles para la formación de imágenes para diagnosticar y para el tratamiento de cáncer de próstata y/o metástasis de la misma.
BR112015028338A2 (pt) métodos de diagnóstico ou de auxílio no diagnóstico e de tratamento da doença inflamatória intestinal
BR112018016697A2 (pt) anticorpo revestido, quimérico ou humanizado, composição farmacêutica, e, método de tratamento.
MA44658A (fr) Procédés et kits de diagnostic et de stratification des risques de patients souffrant d'ischémie
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MX374644B (es) Biomarcadores predictivos de la capacidad de respuesta al receptor de acetil-colina nicotinico alfa-7.
MX370597B (es) Uso de un anticuerpo biespecífico para dll3 y cd3 en el tratamiento y profilaxis de cáncer.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
LT3183268T (lt) Anti-cd123 chimerinis antigeno receptorius (car), skirtas naudoti vėžio gydymui
MX2016002423A (es) Composiciones y metodos de diagnostico para el tratamiento de glioblastoma.
MX2016014306A (es) Marcadores para terapia con lipoproteinas de alta densidad (hdl).
MX2017000840A (es) Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer.
PE20160192A1 (es) Composiciones y metodo para tratar condiciones asociadas con el complemento
MX390764B (es) Ensayos dispersables en agua
BR112015013771A2 (pt) biomarcador preditivo de resposta ao tratamento de ativador do receptor alfa 7 nicotínico de acetilcolina
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
MX2016012219A (es) Agonistas de receptor fgf21 y usos del mismo.
EP3356832A4 (en) BIOMARKERS AND METHOD FOR ASSESSING THE DISEASE ACTIVITY OF PSORIASIS TARTHRITIS
ZA202000242B (en) Targeted defa5 antibody and assay methods for diagnosing and treating inflammatory bowel disease
MX377026B (es) Biomarcadores para la progresión de enfermedades en melanoma.
CO2019002550A2 (es) Anticuerpos anti-gm-csf y usos de los mismos
BR112015031950A2 (pt) métodos para tratamento de câncer de ovário

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]